Celularity Inc. is a biotechnology company that specializes in developing off-the-shelf placental-derived allogeneic cell therapies for cancer and other serious diseases. The primary focus of the company is to harness the unique properties of postpartum placental cells to create advanced cellular therapies. These innovative solutions aim to address unmet medical needs in immuno-oncology, infectious diseases, and degenerative diseases. Celularity Inc. leverages its proprietary technology platform to produce these cellular products, which are designed to enhance immune responses and offer therapeutic benefits. The company's work significantly impacts the healthcare and biotechnology sectors, where there is a continuous demand for transformative treatments that can improve patient outcomes. Situated at the forefront of cell therapy development, Celularity Inc. plays a pivotal role in advancing the understanding and application of cellular medicine, making its contributions highly valuable within the financial markets and the broader biopharmaceutical landscape.